PEDIATRIC PATIENTS: The pharmacokinetics, safety, and efficacy of maraviroc in patients younger than 2 years have not been established. Therefore, SELZENTRY is not recommended in this patient population. Additionally, there are insufficient data to make dosing recommendations for use of SELZENTRY in pediatric patients concomitantly receiving noninteracting medications and weighing less than 30 kg or in pediatric patients concomitantly receiving potent CYP3A inducers without a potent CYP3A inhibitor.

New dosage forms and
strengths of SELZENTRY1

Before prescribing SELZENTRY, a highly sensitive tropism test must be performed on a current sample to confirm the presence of only CCR5-tropic HIV-1. Learn more about the Tropism Access Program (TAP).


Please see full Prescribing Information, including Boxed Warning and Medication Guide, for SELZENTRY.

Reference:

  1. SELZENTRY® (maraviroc) [package insert]. Research Triangle Park, NC: ViiV Healthcare group of companies; 2016.